New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Executive Summary
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.